Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders
- 1 January 1993
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 8 (4), 484-488
- https://doi.org/10.1002/mds.870080412
Abstract
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.This publication has 24 references indexed in Scilit:
- Autoantibodies to GABA-ergic Neurons and Pancreatic Beta Cells in Stiff-Man SyndromeThe New England Journal of Medicine, 1990
- Monoamine oxidase inhibitory properties of milacemide in ratsLife Sciences, 1989
- The Novel Neuropsychotropic Agent Milacemide Is a Specific Enzyme‐Activated Inhibitor of Brain Monoamine Oxidase BJournal of Neurochemistry, 1989
- Autoantibodies to Glutamic Acid Decarboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes MellitusThe New England Journal of Medicine, 1988
- Double‐Blind Study of Milacemide in Hospitalized Therapy‐Resistant Patients With EpilepsyEpilepsia, 1986
- Urea-induced myoclonus: Medullary glycine antagonism as mechanism of actionLife Sciences, 1985
- Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brainLife Sciences, 1983
- Baclofen in the treatment of staff‐man syndromeAnnals of Neurology, 1981
- Effect of glycine on experimental hind-limb regidity in ratsLife Sciences, 1970
- Glycine in the Spinal Cord of Cats with Local Tetanus RigidityScience, 1969